That said I think the academic and pharma communities had engineered themselves into a corner and weren't going to see huge gains (even thogh they are exploring similar ideas) for a number of banal reasons.
What I meant to focus on was that I think DeepMind has less of a pure money/scale advantage in this area than in some others. In something like Go or Atari game-playing, there are many academic groups researching similar things, but their resources are laughably small compared to what DeepMind threw at it. So you might argue that they got good results there in part because they directed 1000x the personnel and compute at the problem compared to what any academic group could afford. In biomed though, their peers in academia and industry are also pretty well-funded.
Here's an exemplar of how I think it evolved well in a cloud world: https://gnomad.broadinstitute.org/
that project adopts many concepts from google and others and greatly improved our analytic capabilities for large-scale genomics.